Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better went public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the fall of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies. Better Therapeutics operates as a fully distributed company combining remote work with periodic team and all-hands in-person meetings. We are headquartered in San Francisco, CA and have employees located in 18 states across the country. For more information, please visit our website at www.bettertx.com